Removal of infected arteriovenous grafts is morbid and many patients do not receive a new access within 1 year.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 10 04 2018
accepted: 09 10 2018
pubmed: 29 12 2018
medline: 28 1 2020
entrez: 29 12 2018
Statut: ppublish

Résumé

Infection of a prosthetic arteriovenous graft (AVG), in patients who have many comorbidities and limited access options, is a feared complication. Our objective was to investigate our contemporary series of infected AVG operations and analyze perioperative and long-term outcomes. We performed a retrospective analysis of AVGs removal, in the setting of infection, from 2005 to 2017 at a single institution. Procedures were classified as total excision if all graft material was removed, subtotal excision if small cuffs remained, and revision if a segment was removed and the graft was revised. Demographics, medical history, perioperative details, and follow-up data were collected. There were 47 patients who underwent an operation for an infected AVG-forearm (27.7%), upper arm (63.8%), and femoral (8.5%). The mean age was 57.7 years and 59.6% were male. The average time from AVG placement to operation for infection was 20.4 months and 85.1% of grafts were placed at our institution. There were 33 patients (70.2%) who had a previous access before the infected graft. Patients with infected AVGs presented with bacteremia (57.4%), sepsis (36.2%), purulent drainage (55.3%), and bleeding at the graft site (31.9%). The majority of grafts (61.7%) were patent on presentation. There were patients 17 (36.2%) who had a fistulogram and 16 (34%) underwent an endovascular intervention within 90 days of graft excision. With regard to procedure type, 40.4%, 38.3%, and 21.3% of AVGs were treated with total excision, subtotal excision, and revision, respectively. Bacterial growth was present in 84.8% of specimens with the most common bacterial species being any Staphylococcus aureus (53.2%), methicillin-resistant S aureus (17%), coagulase-negative S species (10.6%), and Pseudomonas aeruginosa (8.5%). Postoperative intensive care unit admission occurred in 21.3% of cases. There were 25 postoperative complications that occurred in 17 patients (36.2%). The most frequent postoperative complications were nongraft site infections (28%) followed by graft-related events (16%). Mortality at 90 days and 1 year were 2.1% and 12.8%, respectively. Readmissions at 30 and 90 days were 30% and 55%, respectively. Reoperation for infection in the index limb occurred in 10.6% of patients-40% from those who had subtotal excision and 60% from those who underwent revision. New access was placed in 52% of eligible patients at 1 year. Removal of an infected AVG is associated with high morbidity and resource use. Many eligible patients do not receive a definitive access within the first year of graft excision. Close follow-up is necessary to allow opportunities in reassessing for potential new access creation.

Identifiants

pubmed: 30591289
pii: S0741-5214(18)32487-X
doi: 10.1016/j.jvs.2018.10.067
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

193-198

Informations de copyright

Copyright © 2018 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Thomas W Cheng (TW)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Alik Farber (A)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Mohammad H Eslami (MH)

Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pa.

Jeffrey A Kalish (JA)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Douglas W Jones (DW)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass.

Denis Rybin (D)

Department of Biostatistics, Boston University, School of Public Health, Boston, Mass.

Jeffrey J Siracuse (JJ)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Mass. Electronic address: jeffrey.siracuse@bmc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH